16 unchanged sentences
with the same clinical trials related to Rett Syndrome, and which names the Company and Christopher Missling as defendants.
−Removed: Complaint seeks unspecified damages, as well as costs, including counsel and expert witness fees, on behalf of class of investors who
+Added: Complaint seeks unspecified damages, as well as costs, including counsel and expert witness fees, on behalf of a class of investors who
purchased stock of the Company on the NASDAQ during the period February 1, 2022 through January 1, 2024.
16 unchanged sentences
On January 22, 2025, pursuant to a stipulation of the parties, the Court
−Removed: entered an order staying this purported derivative lawsuit until the motion to dismiss filed by defendants in the Initial Action is decided
+Added: entered an order staying this purported derivative lawsuit until the motion to dismiss filed by defendants in the above-referenced class
+Added: action (Quintessa Huey) lawsuit is decided by the U.S.
District Court for the Southern District of New York.
+Added: 14, 2025, another derivative lawsuit asserting state law breach of fiduciary duty and unjust enrichment claims based upon similar allegations
+Added: was filed against the Company (as nominal defendant), Christopher Missling, and members of the Company’s Board of Directors in the
+Added: Supreme Court for the State of New York, County of New York, by another purported shareholder named Evan Levitan.
+Added: The parties to that
+Added: action also have stipulated to a stay of the proceeding until the Court rules on the motion to dismiss in the putative class action lawsuit
+Added: pending in the U.S.
+Added: District Court for the Southern District of New York.
+Added: The New York state court has not yet entered an order pursuant
+Added: to the stipulation of the parties.
know of no other material pending legal or governmental proceedings, other than ordinary routine litigation incidental to our business,
3 unchanged sentences
of such persons, is an adverse party or has a material interest adverse to our or our subsidiaries’ interest.
−Removed: There have been no material changes to the risk factors
−Removed: discussed in “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2024,
−Removed: filed with the SEC on December 23, 2024.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.